Datapoint: Pfizer Seeks Full Approval for Paxlovid

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 7

Pfizer last week announced it has asked the FDA for full standard approval of its COVID-19 antiviral, Paxlovid, in patients at risk of developing severe illness from the virus. Paxlovid is currently Pfizer’s No. 2 best-selling drug, according to data from Evaluate Pharma. Evaluate projects total Paxlovid sales of $29.4 billion in 2022, dropping to $14.8 billion in 2023.

From Evaluate Pharma

0
0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 21

Datapoint: Idaho Completes Medicaid Redeterminations

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 20

Datapoint: Elevance’s New York Subsidiary, Catholic Health Team Up on Value-Based Care

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 19

Datapoint: FDA Approves GSK’s Jakafi Challenger

Read More

The Latest

enhance-patient-assistance-programs

Meet Our Reporters

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today